Lithium for the Treatment of Pediatric Mania

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00442039
• Date of registration: 27/02/2007
• Primary sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Public title: Lithium for the Treatment of Pediatric Mania
• Scientific title: Pediatric Pharmacokinetic and Tolerability Study of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long Term Safety Period, Discontinuation Phase, and Restabilization Period.
• Date of first enrolment: December 2006
• Target sample size: 61
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00442039
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Countries of recruitment

United States

Contacts

• Name: Robert L Findling, MD
• Affiliation: Case Western University

Key inclusion & exclusion criteria

Inclusion Criteria:

1. The patient was between the ages of 7 years and 17 years, 11 months at time of first
dose.

2. The patient met DSM-IV diagnostic criteria, as assessed by a semi-structured
assessment (Kiddie Schedule for Affective Disorders and Schizophrenia - Present and
Lifetime [KSADS-PL]) and a separate clinical interview with a child/adolescent
psychiatrist for manic or mixed episodes in Bipolar I disorder.

3. The patient had a score of = 20 on the YMRS at screening and baseline.

4. The patient and legal guardian understood the nature of the study and were able to
comply with protocol requirements. The legal guardian gave written informed consent
and the youth, written assent.

5. Patients with comorbid conditions (attention deficit hyperactivity disorder [ADHD],
conduct disorder) were eligible to participate.

6. If female: the patient was premenarchal, or was incapable of pregnancy because of a
hysterectomy, tubal ligation, or spousal/partner sterility. If sexually active and
capable of pregnancy, the patient must have been using an acceptable method of
contraception (hormonal contraceptives, intrauterine device, spermicide and barrier)
for at least 1 month prior to study entry and agreed to continue to use one of them
for the duration of the study. If sexually abstinent and capable of pregnancy, the
patient agreed to continue abstinence or to use of an acceptable method of birth
control (either intrauterine device or spermicide and barrier) should sexual activity
commence.

7. If female, the patient had a negative quantitative serum ß-human chorionic
gonadotrophin hormone pregnancy test at screening and a negative qualitative urine
pregnancy test at baseline, if female.

8. Patients with a history of substance abuse were eligible to participate if they
agreed to continue to abstain from drugs during the trial and had a negative drug
screen at screening or prior to baseline.

9. The patient was willing and clinically able to washout (approximately 5 half-lives)
of exclusion medications during the screening period and prior to the administration
of lithium. (No stable patients were asked to discontinue medications.)

10. The patient?s ECG and blood work (including complete blood count [CBC], electrolytes,
etc.) showed no clinically significant abnormalities.

Exclusion Criteria:

1. The patient was clinically stable on current medication regiment for bipolar
disorder.

2. The patient had a current or lifetime diagnosis of Schizophrenia or Schizoaffective
Disorder, a Pervasive Developmental Disorder (Austin Screening Questionnaire score >
15), Anorexia Nervosa, Bulimia Nervosa, or Obsessive-Compulsive Disorder.

3. The patient had a current DSM-IV diagnosis of Substance Dependence.

4. The patient had a positive drug screen at screening and on retest 1-3 weeks later.

5. The patient had symptoms of mania that may have been attributable to a general
medical condition, or secondary to use of medications (eg, corticosteroids)

6. The patient had evidence of any serious and/or unstable neurological illness for
which treatment under the auspices of this study would have been contra-indicated.

7. The patient had any serious, unstable medical illness or clinically significant
abnormal laboratory assessments that would adversely impact the scientific
interpretability or unduly increase the risks of the protocol.

8. The patient had a current general medical condition including neurological disease,
diabetes mellitus, thyroid dysfunction, or renal dysfunction that might have been
affected adversely by lithium, could have influenced the efficacy or safety of
lithium, or would have complicated interpretation of study results.

9. The patient had evidence of current serious homicidal/suicidal ideation such that in
the treating physician's opinion it was appropriately safe for the patient to
participate in this study.

10. The patient had evidence of current active hallucinations and delusions such that in
the treating physician's opinion it was not appropriately safe for the patient to
participate in this study.

11. The patient had concomitant prescription of over-the-counter medication or
nutritional supplements that would interact with lithium or the patient?s physical or
mental status.

12. The patient had any use of psychotropic agents other than stimulants within the
preceding 2 weeks, including antipsychotics, monoamine oxidase inhibitors,
antidepressants; use of stimulants within the preceding week; or fluoxetine or depot
antipsychotics within the past month.

13. The patient had current psychotherapy treatments provided outside the study initiated
within 4 weeks prior to screening.

14. The patient had a previous adequate trial with lithium (at least 4 weeks with lithium
serum levels between 0.8-1.2 mEq/L).

15. The patient had a history of allergy to lithium.

16. The patient had psychiatric hospitalization within 1 month of screening for psychosis
or serious homicidal/serious suicidal ideation.

17. Clinician?s judgment was that the patient was not likely to be able to complete the
study as an outpatient due to psychiatric reasons.

18. The patient had a history of lithium intolerance.

19. Females who were currently pregnant or lactating.

20. Sexually active females who, in the investigators? opinion, were not using an
adequate form of birth control.

21. Patients who were unable to swallow the study medication.

22. Patients for whom a baseline YMRS score of < 20 was anticipated.

23. Patients with an IQ < 70 (determined using the Wechsler Abbreviated Scales of
Intelligence [WASI] Vocabulary and Matrix Reasons Subscales).



Age minimum: 7 Years
Age maximum: 17 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Bipolar I Disorder Without Psychotic Symptoms

Intervention(s)

Drug: Lithium Carbonate

Drug: Placebo

Primary Outcome(s)

Dosing - PK [Time Frame: 8 weeks]

Mean change in YMRS child score [Time Frame: 8 weeks]

Mean change in YMRS parent score [Time Frame: 8 weeks]

Mean Change in YMRS summary score by treatment [Time Frame: 8 weeks]

Rate of treatment emergent adverse events [Time Frame: During administration of study drug]

Secondary ID(s)

DUNS No. 07-775-8407

NICHD-2005-07-01

Source(s) of Monetary Support

Please refer to primary and secondary sponsors